Advanced searches left 3/3

Alpelisib - Europe PMC

Summarized by Plex Scholar
Last Updated: 03 July 2022

* If you want to update the article please login/register

Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: a phase 2 study.

We conducted a phase 2 multi-cohort study of alisib monotherapy in patients with advanced PI3K pathway mutations, including ER+HER2- and TNBC. With a partial response, medical benefit, and increased progression free-survival, the transition free-survival was largely linked to a decrease in PI3K pathway mutant ctDNA levels from baseline to week 8.

Source link: https://europepmc.org/article/MED/35771551


Alpelisib induced interstitial lung disease in a patient with advanced breast cancer.

HISTORY This is a collection of respiratory diseases that cause progressive fibrosis and interstitial lung disease interstitial lung disease. Many of the newly approved oncology drugs have been attributed to the development of interstitial lung disease as an adverse event. In a patient with advanced breast cancer, we report an alpha-induced interstitial lung disease. Case description A 65-year-old breast cancer patient with multiple bone metastases and had been previously treated with letrozole and ribociclib initiated alisib and a fullestrant combination on liver metastases. Naranjo Algorithm's score was 4 based on management and result. Within a week, there was a rapid clinical and radiologic response to corticosteroid therapy. Despite radiological partial response in her liver metastases and a decrease in her tumor marker, Alpelisib was suspended, despite a decrease in her tumor marker and a decrease in her tumor marker. Drug-induced interstitial lung disease is usually a sign of exclusion, and it is particularly difficult to identify during the COVID-19 pandemic among cancer patients.

Source link: https://europepmc.org/article/MED/35730191

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions